Phenyl-substituted nicotinic ligands, and methods of use thereof
Disclosed are compounds and methods of using them to treat a disorder selected from the group consisting of addiction, pain, obesity, schizophrenia, epilepsy, mania and manic depression, anxiety, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder (ADHD), Parkinson's disease, Huntington's disease, Tourette's syndrome, amyotrophic lateral sclerosis, inflammation, stroke, spinal cord injury, dyskinesias, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, autism, mutism, trichotillomania, hypothermia, and disorders of sleep.
1. A method of treating a disorder selected from the group consisting of addiction, chemical substance abuse, alcoholism, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein:
R represents, independently for each occurrence, halogen, C1-C6 alkyl, allyl, C1-C6 alkyloxy, amino, hydroxyl, nitro, cyano, or trifluoro-C1-C4 alkyl;
R 1 represents hydrogen, C1-C6 alkyl, allyl, or C3-C6 cycloalkyl;
R 2 , R 3 , and R 4 independently represent hydrogen, C1-C6 alkyl, allyl, or C3-C6 cycloalkyl, or C1-C6 alkyl substituted with at least one fluorine;
m is 1;
n is an integer selected from 1 and 2; and
z is an integer ranging from 0 to 5.
2. The method of claim 1 , wherein R 1 represents hydrogen.
3. The method of claim 1 , wherein R 2 , R 3 , and R 4 represent hydrogens.
4. The method of claim 1 , wherein n is 1.
5. The method of claim 1 , wherein z is 0.
6. The method of claim 1 , wherein z is 1.
7. The method of claim 1 , wherein z is 2.
8. The method of claim 1 , wherein R represents halogen.
9. The method of claim 1 , wherein R represents halogen, C1-C6 alkyl, C1-C6 alkoxy, amino, or trifluoro-C1-C4 alkyl.
10. The method of claim 1 , wherein the compound of formula (I) is selected from the group consisting of:
11. The method of claim 1 , wherein the compound of formula (I) is
12. The method of claim 1 , wherein the disorder is addiction.
13. The method of claim 12 , wherein the compound of formula (I) is
14. The method of claim 1 , wherein the disorder is chemical substance abuse.
15. The method of claim 14 , wherein the compound of formula (I) is
16. The method of claim 1 , wherein the disorder is alcoholism.
17. The method of claim 16 , wherein the compound of formula (I) is
18. The method of claim 1 , wherein the disorder is tobacco abuse.
19. The method of claim 18 , wherein the compound of formula (I) is